Sanofi, scarred by Roche scrap, hits goal in once-weekly hemophilia A trial and plots race to regulators

Sanofi is fighting back against Roche in the hemophilia A market. Having seen Hemlibra eat into sales of its long-acting factor VIII (FVIII) therapy, Sanofi has now posted positive phase 3 data on its once-weekly successor, positioning the French pharma and partner Sobi to start filing for approvals.